4 Stocks Pushing The Health Services Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 15,720 as of Friday, Feb. 7, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,156 issues advancing vs. 753 declining with 162 unchanged.

The Health Services industry currently sits up 0.6% versus the S&P 500, which is up 0.6%. A company within the industry that fell today was Aetna ( AET), up 2.4%. Top gainers within the industry include St Jude Medical ( STJ), up 2.8%, Smith & Nephew ( SNN), up 2.2%, Boston Scientific ( BSX), up 2.1%, Thermo Fisher Scientific ( TMO), up 2.1% and Becton Dickinson ( BDX), up 1.6%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Laboratory Corporation of America Holdings ( LH) is one of the companies pushing the Health Services industry lower today. As of noon trading, Laboratory Corporation of America Holdings is down $2.10 (-2.3%) to $88.22 on average volume. Thus far, 791,025 shares of Laboratory Corporation of America Holdings exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $87.52-$91.39 after having opened the day at $88.86 as compared to the previous trading day's close of $90.32.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. Laboratory Corporation of America Holdings has a market cap of $7.8 billion and is part of the health care sector. Shares are down 1.1% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Laboratory Corporation of America Holdings a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Laboratory Corporation of America Holdings as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, notable return on equity, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Laboratory Corporation of America Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Cigna ( CI) is down $7.69 (-9.0%) to $77.68 on heavy volume. Thus far, 4.4 million shares of Cigna exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $76.68-$80.93 after having opened the day at $80.11 as compared to the previous trading day's close of $85.37.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $23.5 billion and is part of the health care sector. Shares are down 2.4% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Cigna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Cigna Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Humana ( HUM) is down $1.14 (-1.2%) to $95.52 on average volume. Thus far, 954,643 shares of Humana exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $94.56-$96.57 after having opened the day at $96.01 as compared to the previous trading day's close of $96.66.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Healthcare Services. Humana has a market cap of $14.9 billion and is part of the health care sector. Shares are down 6.4% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts that rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, WellPoint ( WLP) is down $1.48 (-1.7%) to $85.10 on average volume. Thus far, 1.3 million shares of WellPoint exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $84.25-$85.95 after having opened the day at $85.51 as compared to the previous trading day's close of $86.58.

WellPoint, Inc., a health benefits company, through its subsidiaries, offers network-based managed care plans to large and small employer, individual, Medicaid, and senior markets in the United States. The company operates through three segments: Commercial, Consumer, and Other. WellPoint has a market cap of $25.3 billion and is part of the health care sector. Shares are down 6.3% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate WellPoint a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates WellPoint as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full WellPoint Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug